| Author/Editor | Villaran, Cesar; O'Neil, Shane J; Helbling, Arthut; van Noord, Jan A; Lee, Tak H; Chuchalin, Alexander G; Langley, Stephen J; Gunawardena, Kulasiri A; Šuškovič, Stanislav; Laurenzi, Martino | |
| Title | Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction | |
| Type | članek | |
| Source | J Allergy Clin Immunol | |
| Vol. and No. | Letnik 104, št. 3 Part 1 | |
| Publication year | 1999 | |
| Volume | str. 547-53 | |
| Language | eng | |
| Abstract | Background: Montelukast, a leukotriene receptor antagonist, and salmeterol, a long-acting (beta2-receptor agonist, each have demonstrated benefits in the treatment of exercise-induced bronchoconstriction (EIB) in short-term studies. Direct comparisons between these agents in long-term studies are limited. Objective: We sought to compare montelukast and salmeterol in the long-term treatment of EIB. Methods: One hundred ninety-seven patients with mild asthma and a postexercise fall in FEV, of at least 189 were randomized (double-blind) to receive montelukast 10 mg once daily or salmeterol 50 pg twice daily for 8 weeks. Exercise challenge was repeated at day 3, week 4, and week 8 after randomization near the end of the dosing interval for both drugs. The primary efficacy endpoint was the maximal percent fall in postexercise FEVI at week 8. Results: Montelukast was effective in treating EIB without inducing tolerance and provided superior (PS .001) protection than salmeterol at weeks 4 and 8, with comparable protection at day 3. The frequency of respiratory clinical adverse events (P = .046) and discontinuations because of clinical adverse events (P = .052) were less with montelukast. Conclusion: The effect of montelukast was greater than that of salmeterol in the chronic treatment of EIB over a period of 8 weeks in patients with mild asthma as demonstrated by effect size, maintenance of effect, and fewer respiratory clinical adverse events during the study period. Montelukast may be a better alternative to salmeterol as a controller agent for the chronic treatment of EIB. | |
| Descriptors | ASTHMA, EXERCISE-INDUCED BRONCHOCONSTRICTION RECEPTORS, LEUKOTRIENE ADRENERGIC BETA-AGONISTS FORCED EXPIRATORY VOLUME TREATMENT OUTCOME |